Mustang Bio, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Loss per Share (Tables)

Net Loss per Share (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Potentially Dilutive Securities


		For the six months ended June 30,
		2026		2025
Warrants ⁽¹⁾		4,341,094		7,052,001
Options		1,521		1,521
Class A preferred shares ⁽²⁾		333		333
Unvested restricted stock awards		720		720
Unvested restricted stock units		37		112
Total		4,343,705		7,054,687

(1)

For the six months ended June 30, 2025, total warrants exclude 488,452 pre-funded warrants issued in connection with the February 2025 Equity Offering. The shares underlying the pre-funded warrants are included in the basic and diluted net loss per share for the three and six months ended June 30, 2025.

(2)	Class A preferred shares are reflected on an as-if converted basis.